Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J Mark FitzGerald

Showing results (211-220 of 325) with videos related to

Pageof 33
Sort By:
The Journal of Allergy and Clinical Immunology|February 20, 2021
Benralizumab for adolescent patients with severe, eosinophilic asthma: Safety and efficacy after 3 years of treatmentWilliam W Busse, Eugene R Bleecker, J Mark FitzGerald, et al.
The Journal of Asthma : Official Journal of the Association for the Care of Asthma|October 28, 2008
An evaluation of patients' willingness to trade symptom-free days for asthma-related treatment risks: a discrete choice experimentHelen M McTaggart-Cowan, Peilin Shi, J Mark Fitzgerald, et al.
Canadian Respiratory Journal|December 18, 2003
Adjustable maintenance dosing with budesonide/formoterol reduces asthma exacerbations compared with traditional fixed dosing: a five-month multicentre Canadian studyJ Mark FitzGerald, Malcolm R Sears, Louis-Philippe Boulet, et al.
Patient Education and Counseling|February 24, 2020
Asthma and COPD patients' perceived link between health literacy core domains and self-management of their conditionIraj Poureslami, Jessica Shum, Roger Goldstein, et al.
The New England Journal of Medicine|May 17, 2018
Inhaled Combined Budesonide-Formoterol as Needed in Mild AsthmaPaul M O'Byrne, J Mark FitzGerald, Eric D Bateman, et al.
Pharmacogenomics|September 19, 2009
Genetic variations of NAT2 and CYP2E1 and isoniazid hepatotoxicity in a diverse populationSo Yamada, Mila Tang, Kathryn Richardson, et al.
Plos Computational Biology|April 3, 2026
Using cell-specific late-phase asthma mRNA biomarkers to repurpose drugs that concurrently reverse disease signatures across multiple immune cell-typesMingming Zhang, Young Woong Kim, Chen Xi Yang, et al.
Plos One|July 22, 2015
Healthcare Worker Preferences for Active Tuberculosis Case Finding Programs in South Africa: A Best-Worst Scaling Choice ExperimentNathan N O'Hara, Lilla Roy, Lyndsay M O'Hara, et al.
Allergology International : Official Journal of the Japanese Society of Allergology|November 13, 2017
Efficacy and safety of benralizumab in Japanese patients with severe, uncontrolled eosinophilic asthmaKen Ohta, Mitsuru Adachi, Yuji Tohda, et al.
The Lancet. Respiratory Medicine|May 27, 2017
Benralizumab for patients with mild to moderate, persistent asthma (BISE): a randomised, double-blind, placebo-controlled, phase 3 trialGary T Ferguson, J Mark FitzGerald, Eugene R Bleecker, et al.
Pageof 33

Showing results (211-220 of 325) with videos related to

Sort By:
Pageof 33
The Journal of Allergy and Clinical Immunology|February 20, 2021
Benralizumab for adolescent patients with severe, eosinophilic asthma: Safety and efficacy after 3 years of treatmentWilliam W Busse, Eugene R Bleecker, J Mark FitzGerald, et al.
The Journal of Asthma : Official Journal of the Association for the Care of Asthma|October 28, 2008
An evaluation of patients' willingness to trade symptom-free days for asthma-related treatment risks: a discrete choice experimentHelen M McTaggart-Cowan, Peilin Shi, J Mark Fitzgerald, et al.
Canadian Respiratory Journal|December 18, 2003
Adjustable maintenance dosing with budesonide/formoterol reduces asthma exacerbations compared with traditional fixed dosing: a five-month multicentre Canadian studyJ Mark FitzGerald, Malcolm R Sears, Louis-Philippe Boulet, et al.
Patient Education and Counseling|February 24, 2020
Asthma and COPD patients' perceived link between health literacy core domains and self-management of their conditionIraj Poureslami, Jessica Shum, Roger Goldstein, et al.
The New England Journal of Medicine|May 17, 2018
Inhaled Combined Budesonide-Formoterol as Needed in Mild AsthmaPaul M O'Byrne, J Mark FitzGerald, Eric D Bateman, et al.
Pharmacogenomics|September 19, 2009
Genetic variations of NAT2 and CYP2E1 and isoniazid hepatotoxicity in a diverse populationSo Yamada, Mila Tang, Kathryn Richardson, et al.
Plos Computational Biology|April 3, 2026
Using cell-specific late-phase asthma mRNA biomarkers to repurpose drugs that concurrently reverse disease signatures across multiple immune cell-typesMingming Zhang, Young Woong Kim, Chen Xi Yang, et al.
Plos One|July 22, 2015
Healthcare Worker Preferences for Active Tuberculosis Case Finding Programs in South Africa: A Best-Worst Scaling Choice ExperimentNathan N O'Hara, Lilla Roy, Lyndsay M O'Hara, et al.
Allergology International : Official Journal of the Japanese Society of Allergology|November 13, 2017
Efficacy and safety of benralizumab in Japanese patients with severe, uncontrolled eosinophilic asthmaKen Ohta, Mitsuru Adachi, Yuji Tohda, et al.
The Lancet. Respiratory Medicine|May 27, 2017
Benralizumab for patients with mild to moderate, persistent asthma (BISE): a randomised, double-blind, placebo-controlled, phase 3 trialGary T Ferguson, J Mark FitzGerald, Eugene R Bleecker, et al.
Pageof 33